Does Semaglutide Cause Hair Loss? What the Evidence Shows

The research says semaglutide is associated with hair loss in a small share of people, but be careful with confident answers in either direction here, because the honest picture is unsettled.

Hair loss does appear in the prescribing information for Wegovy, the brand semaglutide product for weight management: in the adult trials it was reported in 3% of people taking semaglutide versus 1% on placebo (FDA label via DailyMed). That is an uncommon side effect, not a common one, and there's no established mechanism by which semaglutide would attack hair follicles directly. At the same time, a 2025 letter in the Journal of Cosmetic Dermatology examining alopecia and semaglutide concluded that preliminary evidence suggests an association, while noting that definitive proof is not yet established (Haykal, 2025).

The largest pooled analysis so far points the same way. A 2026 meta-analysis of 17 observational and pharmacovigilance studies found GLP-1 medication use associated with about 40% higher odds of non-scarring hair loss, driven mainly by telogen effluvium and pattern hair loss, with no significant link to alopecia areata. Its authors attribute the signal primarily to weight-loss-related nutritional shortfalls (Viquez Burboa et al., 2026). Observational data like these show association, not cause.

So the accurate statement is narrower than "no, it doesn't": the shedding people report is real, the most plausible explanation is the weight loss rather than the molecule, and researchers are still working it out. Anyone giving you a flat yes or no is ahead of the evidence.

The labels show hair loss for both semaglutide and tirzepatide, and they give the cleanest numbers we have because they come from placebo-controlled trials. Both GLP-1 medicines list hair loss, and both show it in a small minority of people.

• Semaglutide (Wegovy): hair loss in 3% of adults on the drug versus 1% on placebo in the weight-management trials.
• Tirzepatide (Zepbound): hair loss in about 4% to 5% of people on the drug versus 1% on placebo. The label states that hair loss in these patients was associated with weight reduction, and that it was reported more often in women (7.1%) than in men (0.5%). No Zepbound-treated patient stopped treatment because of it (FDA label via DailyMed).

Two cautions keep these numbers honest. First, they come from brand-name trials. Compounded semaglutide and tirzepatide are not FDA-approved and were not studied in those trials, so the figures describe the molecules, not any specific compounded product. Second, the trials were not designed to compare the two drugs on hair, so the small gap between them is not proof that one is gentler on hair than the other. The Zepbound label's own note, that hair loss tracked with weight reduction, fits the telogen effluvium explanation below.

Telogen effluvium is the likely explanation for semaglutide hair loss. Hair grows in cycles. At any moment most of your follicles are in an active growing phase and a minority are resting. Telogen effluvium is what happens when some physiological stressor pushes an unusually large share of follicles into the resting phase at once. A few months later, they shed together — which is why it looks alarming and sudden.

Telogen effluvium is the most common cause of diffuse hair loss, and a wide range of triggers can set it off (Malkud, 2015). The classic ones have nothing to do with GLP-1 medications specifically:

• Rapid or substantial weight loss
• Reduced calorie and protein intake
• Nutrient shortfalls, particularly iron and protein
• Major physical stress — illness, surgery, childbirth, high fever
• Significant emotional stress

Two features explain most of the confusion. First, the delay: shedding typically starts about three to four months after the trigger (Malkud, 2015), so people connect it to whatever is happening now rather than to the weight loss that began in the spring. Second, it's diffuse — a general thinning across the scalp rather than bald patches.

The reassuring part: telogen effluvium is usually self-limiting. Once the trigger resolves, follicles re-enter their growth phase and hair regrows, though it takes months.

Is semaglutide hair loss reversible, and how long does it last?

Semaglutide hair loss that follows the telogen effluvium pattern is generally reversible, and it lasts as long as the trigger plus the months that regrowth takes. The typical timeline runs in three steps: shedding starts about three to four months after weight loss begins, it continues while the trigger is active, and it eases once weight loss slows and intake is adequate. Visible regrowth then takes several more months, because new hair grows slowly. Shedding that is still going strong after about six months, or that leaves patches rather than diffuse thinning, is a different situation and should be examined.

Hair shedding shows up on a GLP-1 for the same reason it does after bariatric surgery, crash diets, and any rapid weight loss, so nothing about it is unique to semaglutide. But GLP-1 medications create the conditions efficiently, for a reason we've written about before: appetite suppression makes it very easy to eat far too little without noticing.

When hunger cues go quiet, it is easy to under-eat for weeks. That produces the combination associated with telogen effluvium — fast weight loss, low protein, and thin nutrient intake. Low protein during rapid weight loss also adds to lean-mass loss, and it's why we argue that under-eating, not over-eating, is the under-discussed risk on a GLP-1.

In other words: the medication may be the occasion, but the modifiable cause is usually how you're eating on it.

What helps with hair shedding on semaglutide is mostly eating enough, especially protein, and giving it time. None of this is a treatment for hair loss, and none of it is a substitute for a physician's assessment. It's the set of things that address the underlying trigger:

• Get enough protein. Protein is the lever most within your control. In a meta-analysis of resistance-training studies, gains in lean mass stopped increasing at around 1.6 grams of protein per kilogram of body weight per day, roughly 0.7 grams per pound (Morton et al., 2018). That study measured muscle, not hair, but it is a useful reference point for the intake that protects lean tissue during weight loss; your physician can set a target that fits you.
• Don't stack a crash diet on top of the medication. The medication is already creating a deficit; adding a steep one compounds the trigger.
• Eat enough overall. Chronic under-eating is the condition to avoid, and it's easy to fall into when appetite is suppressed.
• Ask about nutrient status. Iron, zinc, and vitamin D shortfalls are recognized triggers for telogen effluvium (Haykal, 2025), but supplementing blindly isn't the answer — that's a conversation with your physician, ideally informed by testing rather than guesswork.
• Give it time. Regrowth is measured in months, not weeks, and it lags the correction.

See a physician about hair loss on semaglutide when it does not look like telogen effluvium, because those presentations deserve a proper look:

• Patchy or circular bald spots rather than diffuse thinning, which can point to alopecia areata rather than shedding
• Shedding that continues well beyond six months, or that doesn't improve after weight loss stabilizes
• Hair loss with other symptoms — fatigue, cold intolerance, skin or nail changes
• A receding hairline or thinning at the crown, which can be pattern hair loss rather than shedding; pattern hair loss was also associated with GLP-1 use in the 2026 meta-analysis above

Your physician may also check for the common non-GLP-1 causes of shedding, such as thyroid problems or low iron stores, with blood tests. A physician or dermatologist can distinguish between these; an article can't. If your hair loss is distressing you, that alone is reason enough to have it looked at.

Protocol MD approaches hair loss on a GLP-1 as a side effect to raise with your prescribing physician, along with whether you're eating enough. Protocol MD's semaglutide and tirzepatide are physician-prescribed and compounded. Compounded medications are not FDA-approved and are not the same as the brand-name products. A US-licensed physician reviews your history and decides whether treatment is appropriate, and side effects such as hair shedding are something to raise with that physician, along with whether you're eating enough while taking it.

The Protocol MD GLP-1 program offers compounded semaglutide and compounded tirzepatide, and the physician chooses the molecule. If you're considering treatment, that's where it starts. If you're already on a GLP-1 and something feels off, our guides on why the scale might have stalled and how much you should actually be eating cover the two issues that come up most.

The bottom line is that semaglutide is linked to hair loss in a small share of people, about 3% in the brand trials, most likely not by acting on the follicles directly. What it can do is produce the rapid weight loss and reduced intake that trigger telogen effluvium — a temporary, diffuse shedding that shows up a few months late and usually resolves on its own. The research is still emerging and an association has been reported, so it's worth taking seriously rather than dismissing.

The practical response is unglamorous: eat enough, prioritize protein, don't crash-diet on top of the medication, and get patchy or persistent loss properly evaluated.